Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ongoing bidding war between Novo Nordisk and Pfizer over obesity biotech Metsera.

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

Two groups are fighting for an edge in one of the most lucrative drug classes in the pharmaceutical industry’s history.

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales growth for its blockbuster obesity drug Wegovy, Doustdar has already announced plans to lay off about 9,000 employees worldwide and shutter the company’s cell therapy R&D work.

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera , capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk .